Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) was $3.51 for the day, up 2.03% from the previous closing price of $3.44. In other words, the price has increased by $2.03 from its previous closing price. On the day, 0.66 million shares were traded. MRVI stock price reached its highest trading level at $3.52 during the session, while it also had its lowest trading level at $3.43.
Ratios:
Our analysis of MRVI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.56 and its Current Ratio is at 5.29. In the meantime, Its Debt-to-Equity ratio is 1.50 whereas as Long-Term Debt/Eq ratio is at 1.44.
Upgrades & Downgrades
In the most recent recommendation for the company, Robert W. Baird on February 26, 2025, Downgraded its rating to Neutral and sets its target price to $3 from $9 previously.
Goldman Downgraded its Neutral to Sell on December 05, 2024, while the target price for the stock was maintained at $4.25.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 13 ’25 when Brust Bernd bought 216,212 shares for $3.25 per share. The transaction valued at 702,689 led to the insider holds 466,771 shares of the business.
Brust Bernd bought 157,201 shares of MRVI for $509,331 on Nov 11 ’25. The Chief Executive Officer now owns 157,201 shares after completing the transaction at $3.24 per share. On Nov 12 ’25, another insider, Brust Bernd, who serves as the Chief Executive Officer of the company, bought 93,358 shares for $3.21 each. As a result, the insider paid 299,679 and bolstered with 250,559 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRVI now has a Market Capitalization of 1286032128 and an Enterprise Value of 819812864. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.67 while its Price-to-Book (P/B) ratio in mrq is 2.07. Its current Enterprise Value per Revenue stands at 4.26 whereas that against EBITDA is -10.123.
Stock Price History:
The Beta on a monthly basis for MRVI is 0.33, which has changed by -0.32416505 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, MRVI has reached a high of $6.21, while it has fallen to a 52-week low of $1.66. The 50-Day Moving Average of the stock is 7.82%, while the 200-Day Moving Average is calculated to be 33.77%.
Shares Statistics:
MRVI traded an average of 1.49M shares per day over the past three months and 1466230 shares per day over the past ten days. A total of 144.72M shares are outstanding, with a floating share count of 105.64M. Insiders hold about 27.15% of the company’s shares, while institutions hold 78.15% stake in the company. Shares short for MRVI as of 1763078400 were 13282908 with a Short Ratio of 8.94, compared to 1760486400 on 13427916. Therefore, it implies a Short% of Shares Outstanding of 13282908 and a Short% of Float of 10.879999999999999.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 10.0 analysts currently analyzing and rating the stock of Maravai LifeSciences Holdings Inc (MRVI).The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.02 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.29 and -$0.34 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is -$0.21, with 11.0 analysts recommending between -$0.15 and -$0.34.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 10 analysts. It ranges from a high estimate of $49.6M to a low estimate of $48.7M. As of. The current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $56.56MFor the next quarter, 10 analysts are estimating revenue of $50.6M. There is a high estimate of $65.81M for the next quarter, whereas the lowest estimate is $46M.
A total of 11 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $187.7M, while the lowest revenue estimate was $184.62M, resulting in an average revenue estimate of $185.19M. In the same quarter a year ago, actual revenue was $259.19MBased on 10 analysts’ estimates, the company’s revenue will be $202.57M in the next fiscal year. The high estimate is $218.8M and the low estimate is $191.86M.
